Clinical Trials Logo

Drug-eluting Stents clinical trials

View clinical trials related to Drug-eluting Stents.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05677711 Active, not recruiting - Clinical trials for Coronary Artery Disease

Safety and Efficacy of the Ultimaster Stent

Start date: July 20, 2021
Phase:
Study type: Observational [Patient Registry]

Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis. Ultimaster stent (Ultimaster, Terumo Corporation, Tokyo, Japan) are thin strut, silorimus-eluting, biodegradable copolymer to completely degrade over 3-4 months.

NCT ID: NCT03040934 Active, not recruiting - Clinical trials for Percutaneous Coronary Intervention

Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

Start date: November 10, 2017
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, open-label, randomized controlled clinical trial,aims to assess the safety and effectiveness of the Firehawk™ sirolimus target-eluting coronary stent system with abluminal grooves containing a biodegradable polymer (Firehawk™) comparing the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with total coronary occlusion lesion(s).